Article Text

Download PDFPDF
Single dose of prophylactic oral dextrose gel reduces neonatal hypoglycaemia
  1. Praveen Chandrasekharan1,
  2. Satyan Lakshminrusimha2
  1. 1University at Buffalo, Buffalo, New York, USA
  2. 2Division of Neonatology, University at Buffalo, Buffalo, New York, USA
  1. Correspondence to : Dr Satyan Lakshminrusimha, Division of Neonatology, University at Buffalo, 219 Bryant Street, Buffalo, NY 14222, USA; slakshmi{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on:


Oral dextrose gel is a novel therapeutic option to manage asymptomatic neonatal hypoglycaemia. Previous studies1–3 have shown that the use of 40% buccal dextrose gel along with feeds reduces the need for intravenous dextrose therapy, promotes maternal infant bonding and reduces cost. The ease of administering the dextrose gel via the buccal mucosa2 and improvement in breastfeeding rates have made this a popular therapy for hypoglycaemia and is currently being implemented in nurseries across the world. The incidence of hypoglycaemia is almost 50% in neonates with risk factors, including maternal diabetes, maternal β blocker therapy, large or small for gestational age and …

View Full Text


  • Funding National Institute of Child Health and Human Development (HD072929).

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.